Spanish biotechnology companies Reveal Genomics and Ona Therapeutics have entered a strategic collaboration to advance the clinical development of ONA-255.
ONA-255 is a next-generation antibody-drug conjugate (ADC) designed to enhance cancer treatment precision and efficacy across various tumour types.
The collaboration aims to advance cancer treatment by targeting resistant tumour clones for deeper and more durable responses.
The collaboration is led by Reveal Genomics co-founder and chief scientific officer Aleix Prat, who was instrumental in identifying ONA-255 and generating preclinical data.
Aleix Prat said: “I am thrilled about this collaboration, which bridges groundbreaking therapies with precision medicine.
“By leveraging our combined expertise, we can gain deeper insights into ONA-255’s efficacy, paving the way for more targeted and impactful cancer treatments.”
Under the partnership, Reveal Genomics will conduct a comprehensive molecular analysis of tumour and blood samples from the ONA-255 Phase 1-2 clinical trial.
Using in-house technologies and advanced computational algorithms, the company aims to decode key molecular and genomic biomarkers.
Also, it will provide insights into tumour biology and response mechanisms to ONA-255.
The molecular analysis is expected to define patient populations, identify predictive biomarkers, and deepen the understanding of ONA-255’s mechanism of action.
The insights generated will accelerate its clinical development and open new therapeutic avenues in cancer treatment.
Reveal Genomics co-founder and CEO Patricia Villagrasa said: “Ona Therapeutics is at the forefront of developing next-generation cancer therapies.
“This collaboration marks a key milestone in combining advanced diagnostics with innovative treatments, reinforcing the strategic value of integrating biomarker science early in drug development.
“It also underscores Reveal Genomics’ leadership in driving biomarker strategy and our commitment to shaping new business models that bring precision oncology closer to patients.”
Ona Therapeutics, in collaboration with the US subsidiary of Reveal Genomics, has secured a grant from Spain’s Centre for the Development of Industrial Technology (CDTI).
CDTI is a public entity under the Spanish Ministry of Science, Innovation, and Universities.
The grant is funded by the Plan de Recuperación, Transformación y Resiliencia, supported by the European Union’s (EU) NextGenerationEU initiative.
Ona Therapeutics co-founder and CEO Valerie Vanhooren said: “ADCs have transformed cancer treatment; however, the technology has been applied to a limited number of tumour targets.
“Ona’s tailor-designed ADCs have the potential to define new treatment paradigms and patient populations,resulting in a clear benefit for patients with cancer.
“This partnership with REVEAL GENOMICS combines Ona’s ADC experience with cutting-edge diagnostics with the goal to transform the treatment landscape for aggressive solid tumours.”
